Rethinking side effects of the selective serotonin reuptake inhibitors: Sexual dysfunction and weight gain

Psychiatric Annals

Volumn 28, Issue 2, 1998, Pages 89-97

  Sussman, Norman ^a,b   Ginsberg, David ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NB 20N11 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032364561     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19980201-10     Document Type: Article

References (78)

1. Beasley CM, Sayler ME, Bosomworth C, Wernicke JF. High dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol. 1991; 11:166-174;
2. Beasley CM, Sayler M, Weiss AM, et al. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992; 12:328-333).
3. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356-362.
4. Balon R. Selective serotonin reuptake inhibitors and sexual dysfunction. Primary Psychiatry. 1997;4:28-33.
5. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1993;54:71.
6. Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Portera L, Miller NL, Adler D. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry. 1997;154:1757-1759.
7. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Marcias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23:176-194.
8. Nemeth A, Arato M, Treuer T, Vandlik E. Treatment of fluvoxamine-induced anorgasmia with a partial drug holiday. Am J. Psychiatry. 1996; 153:1365.
9. Rothchild AJ. Selective serotonin reuptake inhibitors-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995; 152:1514-1516
10. Cohen, 1992; Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in-patients switched to bupropion. J Clin Psychiatry. 1993; 54:459-465.
11. th Annual Meeting, New York, New York, May 4-9,1996 (Abstract 716).
12. Balogh S, Hendricks S, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine. J Clin Psychiatry. 1992; 53:212-213.
13. Masand PS, Reddy N, Gregory R. SSRI-induced sexual dysfunction successfully treated with amantadine. Depression. 1994/1995; 2:319-321.
14. Balon R, Yeragaani VK, Pohl R, Ramesh C. Sexual dysfunction and open trial of yohimbine. J Clin Psychiatry. 1993; 54:209-212;
15. Balon R. Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Martial Ther. 1996; 22:290-292.
16. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression. 1994; 2:109-112;
17. Bartlik BD, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors. J Sex Marital Ther. 1995; 21:264-271.
18. Labatte LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: A case report. Ann Clin Psychiatry. 1994; 6:13-15.
19. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1995; 18:320-324.
20. A/2C and 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clinical Neuropharmacology. 1997; 20:210-214.
21. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry. 1994; 164:838-839.
22. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand. 1996; 93:69-70.
23. Gitlin MJ. Treatment of sexual side effects with dopaminergic agents. J Clin Psychiatry. 1995; 56:24.
24. Shrivastava RK, Shrivastava S, Overweg N, Schmitt M. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1995;15:83-24.
25. Nemeroff CB, Ninan PT, Ballenger J, et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression. 1995; 3:163-169.
26. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed patients. J Clin Psychiatry. 1997; 58:146-152.
27. Waldinger M. Dispatches. Primary Psychiatry. 1997.
28. Zajecka J, Fawcett J, Schaff M, Jeffries H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991; 51:25-27.
29. Snyder S. Nitric oxide; first in a new class of neurotransmitters. Science. 1992; 257:494-496.
30. Dawson TM; Dawson VL. Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. Annu Rev Med. 1996; 47:219-227.
31. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature. 1983; 305:627-630,
32. Modell JG. Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration [letter]. J Clin Psychopharmacol. 1989; 9:63-65.
33. Garcia-Campayo J, Sanz-Camllo C, Lobo A. Orgasmic sexual experiences as a side effect of fluoxetine: a case report. Acta Psychiatr Scand. 1995;91:69-70.
34. Cohen AJ, Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. J Clin Psychiatry. 1992; 53:174.
35. McLean JD, Forsythe RG, Kapkin IA. Unusual side effects of clomipramine associated with yawning. Can J Psychiatry. 1983; 28:569-570.
36. Bertschy G, Vande S, Bechter D. Bizourd P. Baillemants et excitation sexualle sous clomipramine. L'Encephale. 1991; 17:515-517.
37. Fluoxetine (Prozac) Product Information. Indianapolis: Eli Lilly; 1998.
38. Paroxetine (Paxil) Product Information. Philadelphia: SmithKline Beecham; 1998.
39. Elmore JL, Quattlebaum JT. Female sexual stimulation during antidepressant treatment. Pharmacotherapy. 1997; 17:612-616.
40. Melis MR, Argiolas A. Role of central nitric acid in the control of penile erection and yawning. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21:899-922.
41. Protais P, Windsor M, Mocaer E, Comoy E. Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Psychopharmacology (Berlin). 1995; 120:376-383.
42. Poggioli R, Benelli A, Arletti R, Cavazroti E, Bertolini A. Nitric oxide is involved in the ACTH-induced behavioral syndrome. Peptides. 1995;16:1263-1268.
43. Melis MR, Succi S, Iannucci U, Argiolas A. Prevention by morphine- and oxytocin-induced penile erection and yawning: involvement of nitric acid. Naunyn Schmiedebergs Arch Pharmacol. 1997; 355:595-600.
44. Zvara P; Sioufi R; Schipper HM; Begin LR; Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res. 1995; 4:209-219.
45. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 1996; 32:653-658.
46. th Annual Meeting, December 8-12,1997, Hawaii).
47. Renodon A, Boucher JL, Sari MA, Delaforge M, Ouazzani J, Mansuy D. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects. FEBS Lett. 1997; 406:33-36.
48. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone. J Clin Psychiatry. 1997; 58:89.
49. Burra P, Ferraresso M, Cadrobbi R, Calabrese F, Cardin R, Parnigotto A, Carraro P, Rigotti P. Effect of L-arginine and oligotide on liver ischemia-reperfusion injury. Transplant Proc. 1997; 29:2992-2993.
50. Nilsson B, Yoshida T, Delbro D, Andius S, Friman S. Pretreatment with L-arginine reduces ischemia/reperfusion injury of the liver. Transplant Proc. 1997; 29:3111-3112.
51. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes; acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther. 1997; 283:684-691.
52. Brown TM, Skop BP. Nitroglycerin in the treatment of the serotonin syndrome. Ann Pharmacotherapy. 1996; 30:191-192.
53. Klein, 1989.
54. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993; 87:141-145.
55. Food and Drug Administration 1993. Summary basis of approval for Paxil (paroxetine). Available from the Freedom of Information Services Inc., 12315 Wilkins Avenue, Rockville, MD 20852-1877.
56. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine. J Clin Psychiatry. 1995; 56:288-296.
57. Amsterdam J, Garcia-Espana F, Goodman D, Hooper MB, Hornig-Rohan M. Breast enlargement during SSRI therapy [abstract]. Biol Psychiatry. 1997; 41:28S.
58. Szarek BL, Brandt DM. A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: A retrospective study of psychiatric inpatients. J Nerv Ment Dis. 1993; 181:702-704.
59. Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull. 1988; 24:220-223.
60. Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, Letizia KA. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obesity Res. 1995; 3:549-557.
61. Fogelson DL. Weight gain during fluoxetine treatment. J Clin Psychopharmacol. 1991; 11:220-221.
62. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol. 1996; 11:273-278.
63. Fichtner CG, Braun BG. Hyperphagia and weight loss during fluoxetine treatment. Ann Pharmacother. 1994; 12:1350-1352.
64. Fernstrom M. Drugs that cause weight gain. Obesity Res. 1995; 3(suppl 4):435S-439S.
65. Ayd FJ. A critical appraisal of chlordiazepoxide. J Neuropsychiatry. 1962; 3:177-180;
66. Greenblatt DJ, Shader RI. Benzodiazepines in Clinical Practice. New York: Raven Press; 1974.
67. Haney M, Comer SD, Fischman MW, Foltin RW. Alprazolam increases food intake in humans. Psychopharmacology. 1997; 132:311-314.
68. Palvimaki E-P, Roth BL, Majasuo H, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology. 1996; 126: 234-240.
69. Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology. 1997; 133:309-312.
70. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB. Regulation ofserotonin-2C receptor G-protein coupling by RNA editing. [letter]. Nature. 1997; 387:303-308.
71. Tecott LH, Sun LM, Akana SF, et al. Eating disorders and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995; 374:542-546.
72. Wong DT, Threlkeld PG, Robertson DW. Affinities of fluoxetine, its cnanthomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 1991; 5:43-47.
73. Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A. 1997; 94:2036-2040.
74. Laakso A, Palvimaki E-P, Kuoppamaki M, Syvalahti E, Hietala J. Chronic citalopram and fluoxetine treatments upregulate 5-HT2C receptors in the rat choroid plexus. Neuropsychopharmacology. 1996; 15:143-151.
75. Maj J, Bijak M, Dziedzicka-Wasylewska M, et al. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology 1996; 127:78-82.
76. Huether G, Zhou D, Schmidt S, Wiltfang J, Ruther. Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry. 1997; 41:1174-1180.
77. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci. 1997; 18:21-25.
78. Lightowler s, Wood M, Brown T, Glen A, Blackburn T, Tulloch I, Kennett G. An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats. Eur J Psychopharmacol. 1996; 296:137-143.